ICER Determines OCA’s Benefit In NASH Might Support Limited Approval

 
• By Joseph Haas
  
Businessman balancing between cost and benefit in business conce
ICER says OCA's risk-benefit ratio might only support use in sicker patients
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Scrip